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INTRODUCTION
Multiple myeloma accounts for 14% of the incidence among
of hematologic malignancies and is frequently involved in old
age (1), and the incidence of multiple myeloma has shown a
tendency to increase since the 1980s in Korea (1, 2). This in-
crease may be the result of the larger old population and im-
proved detection methods.
The effective treatment of myeloma began in the 1960s with
the introduction of alkylating agents, of such as melphalan
and cyclophosphamide (3). Moreover, during the past four
decades, a number of pharmacological agents have been tried
for myeloma treatment. These have included other alkylating
agents (BCNU), topoisomerase inhibitors (doxorubicin and
etoposide), glucocorticoids (prednisolone and dexamethasone),
and anti-tubulin agents (vincristine). The combination of
melphalan and prednisolone used to be considered the main-
stay of myeloma treatment, and produced response rates (RR)
of 50-60%. Median remission duration and overall survival
(OS) were 18 and 30-36 months, respectively (4), but complete
response (CR) was less than 5%, and no more response was
observed after 6 to 12 cycles of chemotherapy (5). Other inves-
tigator reported that the ten-year survival rate was 2.2% (6).
To cure myeloma and improve survival, many protocols and
new modalities of treatment have been developed, and one of
these approaches is high dose therapy (HDT). McElwain and
Powles (7) reported that high doses of melphalan could induce
a high rate of response even in patients with disease refrac-
tory to conventional doses of the drugs. To shorten the myelo-
suppressive period and reduce therapy related mortality, Bar-
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High Dose Therapy Followed by Autologous Peripheral Blood Stem
Cell Transplantation as a First Line Treatment for Multiple Myeloma:
a Korean Multicenter Study
We conducted a phase II multicenter trial to estimate the response and survival
of patients with newly diagnosed multiple myeloma to high dose melphalan therapy
followed by autologous peripheral blood stem cell transplantation. Eligible patients
who had undergone induction with vincristine, adriamycin and dexamethasone
(VAD) should have adequate cardiac, pulmonary and renal function (creatinine <2
mg/dL). Melphalan at 200 mg/m
2 was used as a conditioning regimen. Eighty
patients were enrolled from 13 centers. The median age of the patients was 53 yr
(range; 20 to 68 yr). The initial stage was IA/IIA/IIB/IIIA/IIIB in 3/8/1/54/14 patients,
respectively. Beta2-microglobulin, CRP and LDH were increased in 74, 42 and 34%
of the patients examined. Cytogenetic data were available in 30 patients, and 6
patients showed numeric or structural abnormalities. Two therapy-related mortali-
ties occurred from infection. Among the 78 evaluable patients, CR/PR/MR/NC/PD
were achieved in 48/26/2/1/1patients, respectively. After a median follow-up of 30
months, the median overall and event-free survivals were 66 months (95% CI: 20-
112) and 24 months (95% CI: 18-29), respectively. This study verifies the efficacy
and feasibility of high dose melphalan therapy with autologous stem cell transplan-
tation in newly diagnosed multiple myeloma.
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logie et al. used autologous blood stem cell transplantation
(ASCT) after high dose therapy, and found that this resulted
in reduced myelotoxicity (8). The Intergroupe Francais du
Myelome was the first to conduct a randomized trial, which
demonstrated the superiority of HDT with ASCT, as compared
to conventional chemotherapy (9). In the trial (IFM90), HDT
was found to significantly improve the response rate, and 38%
of patients enrolled in the HDT arm achieved a CR or a very
good partial remission versus only 14% of patients enrolled
in the conventional chemotherapy arm (p<0.001). HDT also
significantly improved event-free survival (EFS) (5-yr EFS 28%
versus 10%, p=0.01), and OS (5-yr OS 52% versus 12%, p=
0.03) in comparison to conventional therapy. In another ran-
domized French trial (10), 190 patients aged 55 to 65 yr were
randomized to receive conventional chemotherapy or HDT.
Although the results of HDT appeared comparable to those
achieved in the IFM90 trial, no significant difference was found
in the OS of the 2 arms due to unexpected survival in the con-
ventional chemotherapy arm (median 55 months with HDT
versus 50 months with conventional chemotherapy). It should
be noted that in this conventional chemotherapy arm, 17
patients received HDT at the time of relapse. By the very fact,
HDT represents a significant improvement, and is current-
ly proposed as part of the front line therapy for patients up
to 70 yrs of age.
No data is available upon HDT in previously untreated
myeloma in Korea. Therefore, a phase II multicenter trial of
HDT with ASCT as a first line treatment for multiple myelo-
ma in newly diagnosed patients was conducted. This study
aimed, to estimate the CR rate and survival, to assess the safety
and feasibility of HDT and to document the prognostic factors
of response in the Korean population.
PATIENTS AND METHODS
Patients
Between April 1997 and March 2002, 80 patients were
enrolled in this study from 13 centers in Korea. The eligibil-
ity criteria were as follows: a) symptomatic multiple myelo-
ma with measurable M-protein, b) age <70 yr, c) an ECOG
performance status of 0-3, d) adequate cardiac, pulmonary, and
renal function before the mobilization (systolic cardiac ejec-
tion fraction ≥50%, FEV1 ≥60% and creatinine <2.0 mg/
dL), e) VAD induction chemotherapy before enrollment (VAD:
vincristine 0.4 mg by continuous intravenous (i.v.) infusion
for 4 days (total 1.6 mg) and adriamycin 9 mg/m2 by contin-
uous i.v. infusion for 4 days (total 36 mg/m2) and dexametha-
sone 40 mg once daily p.o. on days 1-4, 9-12, and 17-20 every
5 weeks).
Prior local radiotherapy was permitted. All patients gave
informed consent and the study was approved by an individual
institutional review boards.
Response Criteria
Response to VAD induction and HDT were evaluated ac-
cording to the EBMT criteria (11). CR was defined as the
absence of M component on immunofixation (or immune elec-
trophoresis) for 6 weeks and 5% or fewer plasma cells in the
bone marrow, with no increase in the size or number of bone
lesions and the disappearance of soft tissue plasmacytomas;
Partial response (PR) was defined as ≥50% decrease of serum
M component and/or a ≥90% decrease of urine M component
for 6 weeks, or a ≥50% reduction of soft tissue plasmacytomas
with no increase in size or number of bone lesions. Minimal
response (MR) was defined as a 25-49% decrease of serum M
component and/or a 50-89% reduction in urine M component,
which still exceeded 200 mg/day for 6 weeks, and/or a 25-49%
reduction of soft tissue plasmacytomas with no increase in the
size or number of bone lesions. No change (NC) was defined
as not meeting the criteria of either minimal response or pro-
gressive disease, and progressive disease (PD) was defined as
a ≥25% increase of serum M-protein, which must have repre-
sented an absolute increase of at least 0.5 g/dL, and/or a ≥25%
increase of urine M-protein, which must have represented an
absolute increase of at least 200 mg/day and have been confirm-
ed by at least one repeated test, and/or a ≥25% increase in
bone marrow plasma cells, which must have represented an
absolute increase of at least 10%, and/or a definite increase in
the size of plasmacytomas or bone lesions, and/or the devel-
opment of a new bone lesions, plamacytomas, or hypercalcemia
(corrected calcium level >11.5 mg/dL). Relapse was defined
as the reappearance of M component on immunofixation or
routine electrophoresis, confirmed by at least one further test,
or ≥5% of plasma cells in the bone marrow, or the develop-
ment of new bone lesions, plamacytomas or hypercalcemia, or
a definite increase in the size of residual bone lesions.
Mobilization and Transplantation
Protocols for peripheral blood stem cells (PBSCs) mobiliza-
tion were decided according to each investigator’s policy. The
minimum recommended CD34+ cell dose was 2.0×106/kg.
HDT was performed with melphalan (100 mg/m2 i.v. infu-
sion over 30 min on two consecutive days -3 and -2; total
200 mg/m2) at least 4 weeks after mobilization. Stem cells
were infused 2 days after the final melphalan dose. G-CSF 5
g/kg daily subcntaneous (s.c) was started from day 1 until the
ANC achieved 1,000/ L for 3 consecutive days. Prophylactic
antibiotics, antifungal and antiviral agents were used accord-
ing to the participating center’s policy. Transfusion and nutri-
tional support were supplied via a central venous catheter. If
neutropenic fever developed, broad-spectrum antibiotics were
administered immediately after cultures of blood and/or spec-
imens of suspicious foci of infection had been taken. Hema-
tologic and non-hematologic toxicities were graded accord-
ing to the modified WHO criteria.
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Post-transplant Follow-up
Response was evaluated 4 weeks after ASCT. Protein elec-
trophoresis and immunofixation (or immune electrophoresis)
of serum and/or urine were performed concomitantly with
bone marrow aspiration and biopsy. If CR had been achieved,
the patient was seen once per month for two months, the once
every 2 months on 3 occasion, and every 3 months thereafter.
If CR had not been achieved, the patient was seen once per
month until CR. At each follow-up visit, patients underwent
a history taking and a physical examination, and complete
blood count, platelet count and liver function testing. Serum
and/or urine protein electrophoreses were screened. If the re-
lapse or progression was confirmed, the further therapy was
at the direction of the participating physicians.
Statistical Analysis
Data obtained up to and including September, 2002 were
analyzed. Response rates were compared using the chi-square
test or Fisher’s exact test. All tests were two-sided. Therapy-
related mortality (TRM) included any deaths within 60 days
of transplantation. Event-free survival (EFS) was calculated
for all patients from the date of induction until the time of
disease progression, relapse, or death, or until the date the
patient was last known to be in remission. OS was defined as
the time from induction until death or the date the patient
was last known to be in remission. CR duration was evaluated
from the time of CR until relapse. Actuarial survival and CR
duration curves were plotted according to Kaplan and Meier’s
method, and the prognostic factors were compared using the
log-rank test. Analysis was performed on an intent-to-treat
basis. All calculations were performed upon SPSS system,
version 10.0.
RESULTS
Patients Characteristics
Table 1 shows the base-line characteristics of the 80 patients
at diagnosis. At that time, bone marrow cytogenetics, CRP,
LDH, and beta2-microglobulin ( 2-MG) were not checked
in 62, 48, 26, and 9% of the patients. Six among the 30 pa-
tients checked for cytogenetics showed abnormalities (Table 2).
After a median 4 (range; 2-6) cycles of VAD, the responses
were 13 CR (16%), 59 PR (74%), 4 MR (5%), 2 NC (2.5%)
and 2 PD (2.5%).
Treatment courses
The protocols used for the mobilization of PBSCs were
cyclophosphamide (CTX) with G-CSF (or GM-CSF)/CTX
and etoposide with G-CSF/VAD with G-CSF/G-CSF only
in 70/6/2/2 patients. One patient refused HDT after mobi-
lization because of poor economy. The median interval between
diagnosis and transplantation was 6 months (3-20) in the re-
maining 79 patients. Transplantation within 1 yr after diagno-
sis was performed in 77 patients. Median infused mononuclear
cells and CD34+ cells were 4.6×108/kg (0.2-24.0) and 4.2×
106/kg (1.5-32.0), respectively. A second infusion of PBSCs
was performed in 2 patients for delayed engraftment. Two
therapy-related mortalities occurred due to infection on days
27 and 30. Before HDT, these two patients were in CR. One
patient had received a second infusion of stem cells but had
not achieved engraftment at time of death. The remaining 77
patients showed ANC recovery (>500/ L) on day 11 (7-31)
after HDT commencement. Transfusion independency of
platelets (>20,000/ L) showed on day 12 (8-60) in 76 patients.
One patient continued to be dependent upon platelet trans-
fusions up to 19 months after transplantation despite myeloid
engraftment. The median transfused packed RBCs and platelet
concentrates were of 2 (0-17) and 24 (0-420) units. There was
no correlation between CD34+ cell dose (more or less than
Sex (M/F) 44/36 55/45
Age (median; range, yr) 53; 20-68
>50 44 54
ECOG PS (1/2/3) 52/20/8 65/25/10
Stage (IA/IIA/IIB/IIIA/IIIB) 3/8/1/54/14 4/10/1/68/18
M component (median; range) 4.9; 0.6-14.3 g/dL
G/A/light chain/D 41/21/12/6 51/26/15/8
/ 42/38 53/47
BM plasma cell >30% 52 65
Hemoglobin <8.5 g/dL 41 51
Platelet <150,000/ L 28 35
Serum calcium >11. 5 mg/dL  8 10
Lytic bone lesions ≥34 2 5 3
LDH >UNL (checked patients) 22 (64) 34
CRP >0.5 mg/dL (checked patients) 19 (45) 42
2-MG >UNL (checked patients) 58 (78) 74
Stage, Durie-Salmon stage; BM, bone marrow; UNL, upper normal limit.
Characteristics Patients No. Percentage
Table 1. Patients and disease features at diagnosis
M 61 46, XY[12]/46, XY, inv(1)(p11q21)[6]
M 55 46, XY[17]/46, XY, t(7:14)(q12:q32)[3]
M 48 43, XY, -8,-18,-20[1]/47, XY, +21[1]/46, XY[4]
F 62 46, XX, del(1)(q32), t(11:14)(q13:q32)[2]/46, XX[1]
F 49 45, X,-X, +1, der(1:16)(q10:p10), dic(1:6)(p11:p25),
t(6:14)(p21:q32),-13[6]/48, idem, +der(14)t(6:14), +15,
+21[8]/45, X,-X,+1, +del(1)(p11), der(1:5)(q10:p10),
t(6:14)(p21:q32), -13[2]/46, XX[4]
F 51 46, X-X, der(1)t(1:?)(q21:?), der(5)t(5:10)(q33:q11.2),
add(6)(q21), add(7)(p13), t(8:14)(q24.1:q32), -10,
der(11)t(11:?)(p15:?), t(11:14)(q13;q32), -16, -17, -20,
+mar1, +mar2, +mar3, +mar4[6]
M, male; F, female.
Sex Age (yr) Cytogenetic findings
Table 2. Cytogenetic abnormalities of six patients
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3.0×106/kg) and the rapidity of engraftment.
Responses
Table 3 demonstrates the responses of the patients. The CR
rate after HDT was 60% by an intent-to-treat analysis. CR
was induced by HDT in 36 patients, and the remaining 12
patients continued in CR. The median duration of CR was 17
months (95% confidence interval (CI):10-25). CR after trans-
plantation was negatively associated with the serum  2-MG
level (p=0.03). CR after HDT was found to be marginally
related to cytogenetic status in 33 patients (p=0.08).
Non-hematologic Toxicity
Toxicities greater than grade 3 are summarized in Table 4.
Types of fever in 42 patients were as follows; 24 of unknown
origin, 11 microbiologically documented infections (MDI)
and 7 clinically documented infections (CDI). Sites of the MDI
were central venous catheter, blood, gastrointestinal tract, skin,
ear, and urinary tract in 3, 3, 2, 1, 1, and 1 patient, respectively.
The etiologic organisms were Gram-positive cocci in seven
patients and Gram-negative rods in four.
Survival
After a median follow-up of 30 months, median OS and
EFS were 66 months (95% CI: 20-112) and 24 months
(95% CI: 18-29), respectively (Fig. 1). Lambda light chain
(p=0.0009), initial anemia (p=0.004), thrombocytopenia
(p=0.004), and hypercalcemia (p=0.01) were associated with
shorter OS. The poor prognostic factors for EFS were initial
thrombocytopenia (p=0.03) and hypercalcemia (p=0.05).
DISCUSSION
This study has several limitations. The first is the timing of
enrollment. At the start of this trial, many investigators had
difficulty in obtaining patients’ consents. Reasons were mainly
economic problems with no guarantee of insurance, and the
fear of the toxicity of ASCT. Therefore, most patients were
enrolled after induction chemotherapy, and therefore, the true
response rate and toxicity of VAD could not be measured. More-
over, patients with high-risk might have dropped out during
the induction. The second is that we lacked base-line data in
most patients. Delayed enrollment made the collection of ini-
tial characteristics difficult, and the evaluation of prognostic
factors influencing response and survival could be performed
only by univariate analysis. The third is that there was no uni-
form protocol for mobilization or for infection prophylaxis.
Although neither serious myelotoxicity nor life-threatening
infection occurred, except in the two TRMs, the ideal method-
ology of ASCT in myeloma could not be inferred.
VAD induction chemotherapy was chosen because of non-
cross resistance with melphalan. The CR rate after VAD was
16%, which was lower than other reports (12), but overall RR
(91%) and median time to CR (3.6 months) were comparable
with that reported previously (12, 13). The main limitation
of VAD induction was the need of the admission for continu-
ous infusion.
The other points concerning HDT with ASCT for myeloma
are as follows; the timing of the transplantation, the condition-
ing regimen, single versus tandem transplants, purging of
stem cells, and maintenance therapy. Since ASCT is also a use-
ful salvage therapy for primary refractory myeloma and for
Infection 40 2* 53
Mucositis 13 3 20
Nausea 16 1 21
Vomiting 12 - 15
Diarrhea 4 - 5
Hepatotoxicity 1 - 1
Renal toxicity - 1 1
*Related to mortality.
Toxicity Grade 3 Grade 4 Percentage
Table 4. Non-hematologic toxicity of grade 3 or 4 in 79 patients
CR 48 60
PR 26 33
MR 2 3
NC 1 1
PD 1 1
TRM 2 3
Total 80 100
Types of response Patients No. Percentage
Table 3. Responses after high dose therapy on an intent-to-treat
analysis
CR, complete response; PR, partial response; MR, minimal response;
NC, no change; PD, progressive disease; TRM, therapy related mortality.
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Fig. 1. Overall survival (OS) and event free survival (EFS) in total
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chemosensitive relapses, the optimal timing is not yet known.
Fermand et al. reported the results of a randomized study
showing no significant difference in OS between early ASCT
and late ASCT (14). Other supportable data are required on
this topic. The optimal conditioning regimen for ASCT also
has not been determined. After the introduction of total body
irradiation (TBI) (8), many conditioning regimens have been
tried. One randomized study, comparing high-dose melphalan
200 mg/m2 with high-dose melphalan 140 mg/m2 plus TBI
in newly diagnosed myeloma (15), found that high-dose mel-
phalan (200 mg/m2) was significantly less toxic (shorter dura-
tion of neutropenia and thrombocytopenia, lower incidence
of grade >3 mucositis, and no toxic deaths versus 5 in the TBI
group). Although the response rate and the EFS were identical,
OS was superior for high-dose melphalan (200 mg/m2). There-
fore, high-dose melphalan at 200 mg/m2 should be preferred
to high-dose melphalan at 140 mg/m2plus TBI. Higher doses
of melphalan alone or in combination with an anti-IL-6 anti-
body have also been explored with encouraging results (16).
The impact of tandem transplantation was well documented
by the largest trial of the Little Rock group (13). In 231 of
newly diagnosed patients, the CR rate increased from 26%
after the first transplant to 41% after the second transplant.
However, several randomized trials except one upon single
versus tandem transplants have failed to prove the superiority
of double transplants (17-20). Because the data of three nega-
tive results obtained to date still appear immature, longer
follow-up is needed. Sensitive immunofluorescence studies or
PCR based techniques have demonstrated that virtually all
PBSCs are contaminated with malignant cells. Two random-
ized studies compared CD 34+ selected PBSCs with unselected
PBSCs. Engraftment was not different in the two groups, and
also failed to prolong EFS or OS (21, 22).
Interferon- may be effective in minimal residual disease
after HDT. One randomized trial showed that progression-free
survival (PFS) and OS were significantly better in an interfer-
on- maintenance arm with a median follow-up of 52 months,
but these differences disappeared with prolonged follow-up
(23). Since the cure of myeloma with a single course of HDT
followed by interferon- is unlikely, new strategies to control
minimal residual disease after HDT are necessary.
As in a IFM90 trial (9) and total therapy with tandem trans-
plants (13), no plateau of the survival curve was observed in
this study. It means that HDT alone has limitations for the
cure of myeloma. Using a larger cohort of 1,000 consecutive
patients, Desikan R et al. confirmed that the independent fa-
vorable features were an absence of chromosome 13 deletion,
low  2-MG, low CRP level and less than 12 months of prior
conventional chemotherapy (24). Plateauing of the EFS and
OS curves were noted in 45% and 60% of patients with all of
these favorable characteristics. In another retrospective analy-
sis of 110 patients treated with HDT, the detection of chromo-
some 13 abnormalities (-13, 13q-) by FISH was the most power-
ful adverse prognostic factor (25). The combination of FISH
analysis, 2-MG and the IgA isotype produced a very powerful
staging system in the context of HDT.
Therefore, risk-based approaches are needed after the making
of an accurate scoring system in myeloma. The mainstay of
these approaches should be HDT with ASCT. In addition, new
molecularly targeted agents, allogeneic stem cell transplanta-
tion, and microenvironment modifiers offer additional tools
for such approaches.
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